Lateral plate mesoderm Anterior-posterior patterning
Introduction
The lateral plate mesoderm (LPM) forms around the middle of the embryo ventral to the somites. By the end of neurulation the LPM will split into two layers; the somatic layer that will form the future body wall, and the splanchnic mesoderm that will form the circulatory system and future gut wall. While the induction and patterning of mesoderm has been a major focus of studies of amphibian development since the initial studies of Sudarwati and Nieuwkoop (1971) , little is known about the development and patterning of the LPM. Initial patterning of the entire mesoderm requires inductive signals originating from the Spemann organizer that help specify dorsal and ventral fate (Kimelman, 2006 ). The mesoderm then begins the process of being further subdivided into distinct regions. Shortly after gastrulation, in Xenopus, the LPM is thought to have only a rudimentary pattern along the anterior-posterior axis. The heart field, representing the anterior-ventral LPM, is marked by the expression of Nkx-2.5 and is being specified at near the end of gastrulation (Nascone and Mercola, 1995; Sater and Jacobson, 1989) . Patterning within the LPM, posterior to the heart field, has not been well described. Between stages 15 and 25, the LPM is responsible for controlling regional patterning within the underlying endoderm, suggesting that the LPM already has pattern. In the absence of LPM, patterning of the endoderm is essentially lost (Horb and Slack, 2001; Zeynali et al., 2000) . Shortly thereafter, further patterning can be discerned within the LPM as the as the blood islands begin to differentiate on the ventral side.
All-trans retinoic acid (RA), the major biologically active retinoid (Mic et al., 2003) , is involved in a diverse array of developmental processes (Clagett-Dame and DeLuca, 2002; Mark et al., 2006) . RA is a small lipophilic molecule that binds the retinoic acid receptors (RARs) that, together with the retinoid X receptors (RXRs), function as ligand activated transcription factors allowing for the expression of retinoic acid responsive genes. In addition to being an activator of gene expression, the RAR/RXR heterodimer is also known to be a necessary transcriptional repressor in the absence of all-trans RA (Koide et al., 2001) . Recently, it has been demonstrated that RA can also bind the orphan nuclear receptor PPARb/d to activate expression independent of the RARs (Schug et al., 2007) . RA signaling is known to pattern many tissues in development; in particular RA is important in patterning the neural tube, somites, heart, limb bud and gut tube (Collop et al., 2006; Mic et al., 2003; Moreno and Kintner, 2004; Niederreither et al., 2002; Wilson et al., 2003; Zeynali and Dixon, 1998) . In Xenopus, if RA signaling is altered before gastrulation using pharmacological agents, by use of antisense morpholinos, or by injection of dominant-negative or constitutively active receptors, the size of the head is altered (Koide et al., 2001) . Starting prior to gastrulation and continuing after, RA is able to disrupt key cardiac transcription factors in the heart (Collop et al., 2006; Jiang et al., 1999; Keegan et al., 2005) and recent evidence suggests that RA signaling is essential for interaction between the limb and heart fields, two distinct regions of the LPM (Waxman et al., 2008) . However, a role for RA in patterning the remaining LPM has not been described.
We provide evidence for an early anterior-posterior patterning event within the LPM during the neurula stage embryo of Xenopus. This pattern is visualized by the expression domains of the transcription factors Nkx-2.5 and FoxF1 in the anterior LPM, Hand1 in the anterior and extending through the middle LPM, and Xsal-1 in the posterior LPM. We also demonstrate that the size and position of each is dependent on RA signaling. Treatments that alter the level of RA signaling have a converse effect on domains in the anterior LPM and the posterior LPM. We propose that RA signaling is directly responsible for regulating the size of the broad, anterior posterior domains within the LPM.
Results

2.1.
Xsal-1, Hand1, FoxF1, and RALDH2 have restricted expression domains within the LPM Previously we have found that Hand1, a gene used as a pan LPM marker in zebrafish (Keegan et al., 2005) , is expressed in the anterior and middle LPM in Xenopus; however we also demonstrated a region in the posterior LPM that was Hand1 negative ( Fig. 1A ; Collop et al., 2006) . There also exists a region in the anterior LPM at the ventral midline that is devoid of expression creating a hole in the staining pattern just posterior to the heart region ( Fig. 1A) . A hole has previously been demonstrated in this area for the expression domains of FoxF1 at later stages (Tseng et al., 2004) and for Scl2 expression (Kumano et al., 2006) , however its functional relevance is thus far unknown.
In order to better understand the LPM region that lacks Hand1 expression, we looked for markers that may be restricted to the posterior LPM. In chick (Sweetman et al., 2005) and mouse (Nishinakamura et al., 2001) , sal-1 appears to have an expression pattern that suggests posterior mesoderm and so we explored the expression of Xsal-1 in the LPM. Xsal-1 expression has previously been described in the nervous system and limb buds (Hollemann et al., 1996) and our expression analysis showed the same restricted expression pattern within the neural tube. However, we were able to extend those results to include expression in the posterior LPM that corresponds to the region posterior to Hand1 (Fig. 1B) . When comparing embryos, it appears that there is some overlap between the Hand1 and Xsal-1 domains; nevertheless, a significant portion of the Xsal-1 positive domain is Hand1 negative. Xsal-1 expression in the posterior LPM is transient and is not detectable shortly after neural fold closure (stage 20). Subsequent sectioning of embryos assayed for Xsal-1 and Hand1 confirmed that the expression is in the LPM (Supplemental Fig. 1 ).
Next, we compared these patterns to other genes, expressed in the LPM, that have had restricted expression domains described. Two other transcription factors, FoxF1 and XNkx-2.5, are known to have restricted expression domains marking the anterior-dorsal and anterior-ventral LPM, respectively (Koster et al., 1999; Tonissen et al., 1994) . Although not restricted to the LPM, the enzyme responsible for retinoic acid synthesis, RALDH2, is also known to have a restricted expression domain within the LPM along the anterior and dorsal edges ( Fig. 2A ; previously described (Koster et al., 1999) ).
The LPM is usually viewed as a uniform tissue along the anterior-posterior axis (with the exception of the heart field marked by XNkx-2.5 at the anterior end) during the neurula stage of embryogenesis. However, the domains of XNkx-2.5, FoxF1, Hand1 and Xsal-1 clearly demonstrate that this tissue has a distinct anterior-posterior pattern early in development (Fig. 2B ).
2.2.
The LPM pattern is RA responsive
Since RALDH2 is regionally expressed in the LPM, and RA is known to be necessary for a number of different patterning processes throughout development, we wished to test if RA signaling was involved in generating this early LPM pattern (Fig. 2) . We exposed post-gastrula embryos to exogenous RA, RAA, or a DMSO carrier control for a short window of time (stage 14-20) and assayed by whole-mount in situ hybridization for changes in the domain size of our LPM markers. We observed an expansion of the anterior-dorsal marker FoxF1 along the anterior-posterior axis, particularly at the dorsal edge of this domain ( Fig. 3E and F) . When embryos were exposed to RAA the FoxF1 expression domain was essentially abolished ( Fig. 3D and E) . However, no obvious and consistent changes were observed in the anterior-ventral XNkx-2.5 expression domain at this stage ( Fig. 3A-C) although differences have been previously described in later stages (Jiang et al., 1999) .
As we have previously observed (Collop et al., 2006) , the normal inverted saddle shape of the Hand1 domain is expanded towards both anterior and posterior poles of the embryo under exogenous RA conditions, and reduced when RA signaling is blocked by addition of RAA ( Fig. 3G-I ). In addition, at the anterior end of the Hand1 expression domain, the hole at the ventral midline of DMSO controls is absent in embryos treated with RA (Fig. 3L) . Finally, when embryos are exposed to RA, the posterior and dorsal most regions of the Hand1 domain stain darker in all cases when compared to the rest of the domain (Fig. 3I) suggesting that Hand1 is being more highly expressed along the posterior-dorsal border of the domain. In contrast, we observed a reduced Hand1 domain in the RAA treatments, becoming much narrower along the anterior-posterior axis. There were no marked differences in staining intensity within the Hand1 expression domains of RAA-treated embryos (Fig. 3G) . Furthermore, double in situ hybridization demonstrated that the Hand1 domain overlaps with most of the FoxF1 domain (Supplemental Fig. 2, Supplemental Fig. 4) .
In contrast to FoxF1 and Hand1, when the embryo is exposed to exogenous RA, the Xsal-1 LPM expression domain is lost (Fig. 3O) . Treatment with RAA however, had no obvious effect on the Xsal-1 expression domain in the LPM (Fig. 3M) . The previously described Xsal-1 expression pattern (Hollemann et al., 1996) in the neural tube was also changed with altered RA signaling (Fig. 3R,S) . Double in situ hybridization using probes for Hand1 and Xsal-1 demonstrated that no gap existed between the staining domains of the middle Hand1 and posterior Xsal-1 domains (Supplemental Fig. 3 , Supplemental Fig. 4 ). While we could not rule out a region of overlap between the two markers, it is clear that there exists a region which is Xsal-1 positive but Hand1 negative in the posterior LPM.
As AGN194301 is an RARa selective antagonist, it remained a possibility that we did not block all retinoic acid signaling. Therefore, we also tested the effect of adding the pan RAR antagonist, AGN193109 (Supplemental Fig. 5 ). In each case, the two different antagonists gave results that were indistinguishable. Since our exogenous RA treatments were above the physiological concentrations of RA, we wanted to test whether altering RA levels by inhibiting the function of CYP26 (with ketoconazole, thereby inhibiting RA breakdown) or RALDH2 (with citral or DEAB, inhibiting RA synthesis) would alter LPM patterning. The pharmacological approach was used rather than antisense morpholinos or use of dominant-negative RA receptors, because those experiments would entail disruption of RA signaling prior to gastrulation and would necessitate altering overall embryonic anterior-posterior patterning (Koide et al., 2001) . Therefore, those experiments would complicate any phenotype we observed in our postgastrulation patterning event. Both FoxF1 and Hand1 had their expression domain reduced when the embryos were treated with either DEAB or citral (Fig. 4) as would be expected if endogenous levels of RA are increased. No consistent changes were observed in the expression pattern of FoxF1 or Hand1 when the embryos were treated with ketoconazole ( Fig. 4F and I) when compared to controls (Fig. 4E and H) . No obvious changes in the expression domains of either Nkx-2.5 or Xsal-1 were observed with either treatment (Fig. 4A -D, M-P). These results indicate that inhibition of endogenous RALDH2 causes a change in the size of the Hand1 and FoxF1 expression domains. However, inhibition of Cyp26 appears to have little effect on the expression domains within the LPM. We have tested the effectiveness of our ketoconazole treatment by examining the expression of Cyp26 and we found that, as expected, the treatment resulted in an expansion of Cyp26 expression throughout the embryo (data not shown).
2.3.
Retinoic acid directly affects the LPM It has been previously established that the lateral plate mesoderm receives instructive signals from the dorsal mesoderm; for example, signals establishing the left-right axis originate from the node and are passed onto the LPM (Schweickert et al., 2007) . Therefore, it was a distinct possibility that RA could act on the dorsal mesoderm, and that changes to the LPM are thus secondary. To test whether RA directly alters the LPM, we created ventral tissue explants lacking dorsal tissue. These explants, lacking any signaling input from dorsal tissue, were then treated with RA or RAA, and assayed for changes in the expression domains of Hand1 and Xsal-1. Both Hand 1 and Xsal-1 LPM expression domains were altered under exogenous RA treatments even in the absence of dorsal tissue implying that RA is directly affecting the ventral side (Fig. 5) . As the explants could be laid flat after staining, we were able to measure the total area of the Hand 1 (Fig. 5D ) expression domain. We found that total area of Hand1 expression was significantly different (p < 0.05) between all treat- Whole-mount in situ hybridization for Nkx-2.5 (A-C) demonstrates little change under the RA treatment (C), as compared to the DMSO control (B). In contrast, the expression domain of the anterior-dorsal marker FoxF1 (D-F) extends further to the posterior end of the embryo under exogenous RA conditions (F) and reduced under treatment with the RAA (D) as compared to the DMSO control (E). Similarly, the middle marker Hand1 (G-L) demonstrates a reduced expression domain under the RAA treatment (G), while the domain is expanded when treated with RA (I) as compared to the DMSO control (H). Note that when viewed from the side (G-I), the greatest expansion in the Hand1 domain is on the dorsal edge, where there is also increased staining intensity (arrowhead), when treated with RA. In contrast, when viewed from the side (M-O), the lateral Xsal-1 domain is virtually absent under treatment with RA (O) when compared to either RAA-treated (M) or control embryos (N). When viewed from the anterior end (Q-S), other areas of Xsal-1 expression are also affected by RA. The banded expression in the developing brain is reduced and there is increased expression in staining in presumptive ganglia when compared to RAA-treated (Q) or control embryos (R). b ments. Although significant, the differences between treatments appear small. The small changes are due to the fact that the shape changes are most dramatic on the dorsal half of the expression domain whereas changes on the ventral side are much less apparent. The Xsal-1 domain was found to be present in the DMSO control explants and absent in RA treated explants as is found in whole embryo treatments ( Fig. 5E and F) . Therefore, RA can pattern the LPM independent of signals from the dorsal side of the embryo.
As the RARs function as ligand activated transcription factors, we wished to determine if RA signaling was directly regulating Hand1 and Xsal-1 expression. Embryos were treated with cycloheximide to inhibit protein synthesis 15 min prior to treatment with RA (Cascio and Gurdon, 1987) . If RA is not acting through RARs directly bound to the promoter regions of Hand1 or Xsal-1, their expression should not be altered. Following in situ hybridization, we observed that addition of RA altered the Hand1 domain even in the presence of cycloheximide, suggesting that RA is acting directly on Hand1 expression (Fig. 6 A-D) . In contrast, RA did not alter the size of the Xsal-1 domain when cycloheximide was present, while the RA alone markedly reduced the expression domain (Fig. 6E-H ). The reduction of the Xsal-1 domain was not as obvious as in previous experiments (Fig. 3) because this treatment was limited to one hour before fixation due to the toxic effects of cycloheximide whereas the previous experiments show changes after exposure to RA for at least 4 h. The lack of an RA effect on Xsal-1 expression in the presence of cycloheximide suggests that the effects of RA on the posterior Xsal-1 domain are indirect.
2.4.
The anterior-posterior patterning modifications in the LPM are permanent
Since the observed alterations to the LPM are occurring within 4-5 h, we wished to test if these changes are permanent or if they are transient and are reprogrammed at later stages. We exposed early neurula embryos to RA or RAA, and cultured them until the neural tube closed. In order to then restrict abnormal RA levels to between Nieuwkoop stages 14-20, equimolar RAA was added to the embryos which had previously been treated with RA, and RA was added to RAA-treated embryos effectively neutralizing either treatment after about four hours (Supplemental Fig. 6 ; (Collop FoxF1 and Hand1 (Fig. 1A) but not Xsal-1 (Fig. 1B) expression persists in the LPM after the early tailbud stage; therefore, we could only assay for permanent alterations in the FoxF1and Hand1 expression domains. To extend the observations of altered patterning within the posterior LPM, we also assayed for the expression of two additional transcription factors that are expressed in the LPM at later stages with restricted expression domains: XhoxC-10 and Pitx2. Pitx2 is expressed in the anterior to middle LPM during the late tailbud stages (Campione et al., 1999) . XhoxC-10 is normally expressed in the posterior half of the LPM at the mid to late tailbud stage (Christen et al., 2003) .
The FoxF1, Pitx2, and Hand1 domains extended further posterior in RA treated embryos when compared to DMSO control treated embryos (Fig. 7) . Embryos exposed to RAA during the same time window demonstrated a restriction of the expression domains of these three transcription factors towards the anterior end of the embryo. The lengths of the expression domains from the cement gland to the posterior extent of the expression domains were compared to the length from the cement gland to the point where the proctodeum meets the somites. This confirmed our observations and the changes Fig. 6 -Changes in Xsal-1 but not Hand1, due to altered RA signaling, are blocked by the addition of cycloheximide. Embryos treated with cycloheximide had no change in the expression of either Hand1 (B) or Xsal-1 (F) when compared to control embryos (A and E). Expansion of the Hand1 domain, when treated with RA (C), was also observed in embryos treated with both RA and cycloheximide (D). When the embryos were treated with RA for one hour, there was a reduction in the Xsal-1 expression domain although not the severe loss seen in the 4-5 h treatments (G). In the presence of cycloheximide, the reduction in the Xsal-1 domain was not observed (H). In contrast, the expression domain of Xsal-1 under treatment with RA and cycloheximide is not reduced to the extent seen in RA alone (H). In each panel the left lateral side is shown with the anterior end to the left, dorsal to the top. Cycloheximide (Cx). Fig. 5 -Altered RA signaling alters the expression of Hand1 and Xsal-1 in the absence of dorsal tissue. As in the embryo, the Hand1 expression domain area was found to be enlarged under RA treatment (C) and reduced with RAA (A) when compared to controls (B). Measurements and comparison of the total staining area confirmed that this change was statistically significant (D; p < 0.05; n > 10 embryos/treatment). Ventral explants also show the same lack of Xsal-1 expression in the LPM (arrows) when treated with RA (F) when compared to control explants (E) suggesting that the RA is acting directly on the LPM to alter the expression domains of Hand1 and Xsal-1. Explants are oriented with the anterior pole toward the top.
in the length of the expression domains were significantly different for FoxF1 (Fig. 7O) , Pitx2 (Fig. 7P) , and Hand1 (Fig. 7Q) (p < 0.05).
The anterior edge of the XHox-C10 expression domain moved forward under treatment with RAA ( Fig. 7J-K) . This displacement was measured by taking a ratio of the length from the back of the body axis to the front of the expression domain to the length of the body axis (cement gland to proctodeum/somite junction) and was found to be significantly different ( Fig. 7R ; p < 0.05). However, RA had no effect on the expression domain of XhoxC-10 (Fig. 7K-L) . Therefore, altered RA signaling, restricted to the four hour time window Fig. 7 -The changes to the LPM patterning persist after temporally limited alterations in RA signaling. Experimental changes in RA signaling were limited to between stages 14-20 and the embryos were fixed at stage 34-36 for in situ hybridization for FoxF1 (A-C), Pitx2 (D-F), Hand1 (G-I), and HoxC-10 (J-L). The expression domain is reduced under treatment with RAA (A, D, and G), and expanded under RA (C, F, and I) as compared to the DMSO controls (B, E, and H) for all of FoxF1, Pitx2, and Hand1. While the domain of the posterior marker HoxC-10 was anteriorly displaced under RAA (J) as compared to DMSO controls (K), the domain is unaffected under treatment with RA. In each case, the lengths of the domains were measured as a ratio of the length from the cement gland to the most posterior point of LPM staining (x) to the length from the cement gland to the back of the body (y) for the anterior FoxF1, Pitx2, and Hand1 (M). The differences in the length of the staining domain were found to be significant (O, P and Q; p < 0.05; n > 15) between treatments (where *, **, and *** represent statistically significant groups). HoxC-10 was similarly measured (N) using the length of the body axis from the cement gland to the back of the body axis (y), however the length of the domain was measured from the back of the body axis to the anterior edge of the domain (z). The length was found to be significantly different between the DMSO controls and the RAA treatment (p < 0.05; n > 15) however no significant difference was found between RA treatments and controls (R). In all embryos the left lateral side is shown, with the anterior pole to the left, dorsal to the top.
between stages 14 and 20, was sufficient to permanently alter the expression domains of our anterior LPM markers extending their expression domains further posterior. Conversely, decreased RA signaling restricted the expression domains of all of the anterior-middle markers, and extended our posterior marker, XhoxC-10, further anterior.
Discussion
Anterior-posterior patterning of the neurula stage LPM
Patterning within the early LPM is poorly understood. While the heart field is identifiable in the anterior LPM at the neurula stage, no other domains have been described in detail at this stage of development. We now demonstrate a clear subdivision of LPM into smaller domains using the expression of specific transcription factors at the neurula stage of development. We describe four distinct domains: an anterior-ventral Nkx-2.5 expression domain, an anterior-dorsal FoxF1 domain, an anterior-middle Hand1 domain and posterior Xsal-1 domain (Fig. 2) . Although these domains are not mutually exclusive of each other, this pattern in the LPM suggests that significant anterior-posterior patterning within the LPM is taking place earlier than previously thought. This patterning event may not be limited to Xenopus development as homologs of Nkx-2.5, Hand1, FoxF1, and Xsal-1 have been characterized in similar expression patterns in other vertebrates (Lints et al., 1993; Mahlapuu et al., 2001; Srivastava et al., 1995; Sweetman et al., 2005) .
3.2.
Retinoic acid and patterning of the LPM Our results demonstrate that the size of the anterior-middle domains of the LPM are in part controlled by retinoic acid (Fig. 3) . Our evidence supports the hypothesis that retinoic acid is not normally a posteriorizing factor at this stage (Maden, 1999) ; instead there exists high concentrations in the anterior and dorsal LPM corresponding to expression of RALDH2 ( Fig. 7a; (Chen et al., 2001) ) and that this RA may diffuse towards the posterior-ventral pole of the embryo. The extent of any RA diffusion is difficult to determine. The FoxF1 domain would not seem to require any diffusion as it corresponds very well with the size of the RALDH2 domain, as do the anterior-dorsal borders of Hand1 expression. However, the posterior limit of the Hand1 domain does move more anterior when RA signaling is blocked (Fig. 3) suggesting that RA plays a direct role in that process. However, we cannot rule out the possibility that other signal inputs are essential for defining the posterior Hand1 border. Indeed, it is highly unlikely that a concentration gradient of a single morphogen can give rise to a stable axial pattern (Kerszberg and Wolpert, 2007) . We are actively looking at other signaling systems that may also act on the LPM domains.
The inability of ketoconazole to significantly alter the expression domains of FoxF1 and Hand1 (Fig. 3) is not unexpected since Cyp26 is not expressed in the middle of the embryo between stages 14 and 20, although there is strong expression around the very posterior end of the embryo (Hollemann et al., 1998) . We propose that RA is directly acting to modify anterior-dorsal LPM by regulating transcription factors expressed in those areas. This is supported by our observation that decreasing the level of RA signaling, by inhibiting endogenous RALDH2, leads to reductions in the FoxF1 and Hand1 domains (Fig. 4) suggesting that endogenous RA is required. Furthermore, RA appears to directly regulate Hand1 since its domain is still RA responsive when embryos are pre-treated with cycloheximide. While FoxF1 was essentially absent after treatment with RAA, Hand1 expression remained quite strong in the center of its domain indicating that other factors are clearly essential for the expression of Hand1. The role of RA appears to be to regulate the size and position of the anterior and middle LPM expression domains.
In contrast to anterior LPM patterning, addition of RA causes a loss of the posterior Xsal-1 domain. When the embryo was pre-treated with cycloheximide prior to addition of exogenous RA or when endogenous RA signaling is increased by addition of ketoconazole, the Xsal-1 domain remains unchanged. This suggests that RA does not directly pattern the posterior Xsal-1 domain. In the chick, sal-1 expression has been shown to require FGF signaling (Farrell and Munsterberg, 2000) . FGF and RA signaling acting in opposition is a common theme in development (Shiotsugu et al., 2004; Wilson and Maden, 2005) and this suggests that FGF may be an excellent candidate for regulating Xsal-1 expression in the posterior LPM.
Since the posterior LPM is responsive to exogenous treatments of RA, one or more of the RARs should be expressed in this region. This is indeed the case (Escriva et al., 2006; Koide et al., 2001) , along with Cyp26 (Chen et al., 2001; Hollemann et al., 1998) and repression of RA responsive genes through unliganded RARs may be necessary for proper posterior positional identity. This is similar to a mechanism previously proposed in mid-brain patterning (Koide et al., 2001) .
Recently, patterning within the anterior LPM, utilizing Nkx-2.5 and zebrafish Hand2 as markers, has been described suggesting that this process plays a role in patterning the heart (Schoenebeck et al., 2007) . In both zebrafish (Keegan et al., 2005) and Xenopus (Collop et al., 2006) , RA alters the size of the heart field in the early LPM. Furthermore, our results are in agreement with recent experiments in zebrafish which demonstrates that the limb field, an LPM region, can restrict the size of the heart field and that retinoic acid regulates this process pattern (Waxman et al., 2008) . Our results extend these observations and suggest that the entire LPM may undergo coordinated patterning at an early stage of development and that RA is a significant component of the patterning mechanism. A great deal of work has been done on trying to understand patterning of the heart and the role of RA in that pattern (Jiang et al., 1999; Keegan et al., 2005; Waxman et al., 2008; Xavier-Neto et al., 2001) . However, this patterning should not be viewed in isolation. Instead, heart patterning may be a subset of overall LPM patterning.
3.3.
Significance of the LPM pattern
The expression domains that we have observed in the neurula stage LPM of Xenopus do not correspond to any defined structures and so the significance of this pattern is not readily apparent. However, the LPM is responsible for defining the anterior-posterior pattern of the gut (Horb and Slack, 2001) and retinoic acid appears to alter gut patterning in both a mesoderm and endoderm dependent manner (Pan et al., 2007) . As our explants contain endoderm, it remains possible that RA signals acting directly on the endoderm could influence the patterning of the LPM. However, our results from the cycloheximide experiments (Fig. 6) suggest that the effects on the Hand1 domain are direct. We cannot rule out a role for endodermal signals in the Xsal-1 domain. It would appear that the source of RA responsible for proper mesodermal patterning would be the same for any endodermal patterning because of the restricted expression of RALDH2 at that stage.
Two of the transcription factors that define the LPM pattern, FoxF1 and Xsal-1, can also be linked to endodermal defects. Disruption of FoxF1 by use of antisense morpholinos results in severe gut abnormalities (Tseng et al., 2004) and we have observed that the same treatment with RAA that disrupts FoxF1 expression will also result in gut abnormalities (Supplemental Fig. 7 ). Gut defects induced by a loss of RA signaling appear distinct from those observed with RA treatment but similar to those observed with the loss of FoxF1. In humans, disruptions in sal-1 gives rise to a spectrum of developmental defects called Townes-Brockes syndrome which includes defects in posterior gut morphogenesis, such as a displaced anus (Kohlhase et al., 1998) . Given the role of LPM in patterning endoderm and the location of Xsal-1 expression at the posterior end of the LPM, it is plausible that this aspect of the Townes-Brockes syndrome may be due to a loss of sal-1 activity in the posterior LPM.
We have demonstrated that there is considerable complexity in the LPM, a region of the embryo that is usually viewed as relatively uniform with the exception of the heart-forming region at the anterior end. The relative size of these domains is at least partially coordinated by retinoic acid, a molecule known to be involved in multiple anterior-posterior patterning events. Given the importance of derivatives of the LPM, a greater understanding of how it is patterned and the role of retinoic acid in that process will be of considerable interest for future investigation.
4.
Materials and methods
Embryo collection
Female Xenopus laevis frogs were injected with 600-700 IU of human chorionic gonadotropin. Eggs were collected the following morning and fertilized in vitro by adding minced testis to the 80% Steinberg's solution they were being cultured in for twenty minutes. Embryos were dejellied in 2.5% cysteine, pH 8.0, and cultured in 20% Steinberg's solution. Staging of embryos was according to Nieuwkoop and Faber (1994) .
Embryo treatments
Embryos were treated with 1 lM all-trans RA (Sigma), 1 lM RARa antagonist (RAA, Allergan #194301), or 1 lM pan RAR antagonist (Allergan #193109) (Collop et al., 2006; Teng et al., 1997) in 20% Steinberg's solution at stage 14, and cultured until stage 20. Stock solutions for both RA and RAA were 1 mM dissolved in DMSO, and therefore a control treatment was performed with 0.1% DMSO in 20% Steinberg's solution. Ketoconazole was used to inhibit Cyp26, the enzyme primarily responsible for RA catabolism, at a concentration of 50 lM. RALDH2, the enzyme primarily responsible for synthesis of RA, was inhibited with either 120 lM citral or 20 lM DEAB. To study the effects of early RA treatments on later LPM patterning, we developed a strategy to restrict our alterations of RA signaling from stage 14 to 20. Embryos were first exposed to the RA or RAA treatments at stage 14 and at stage 20; they were then treated with an equal concentration of RAA (where embryos were first treated with RA at stage 14) or RA (where they had been treated with RAA) for 30 min, before being transferred to 20% Steinberg's solution without exogenous RA. The neutralization treatments with both RA and RAA were necessary since simple washes were found to be insufficient to eliminate exogenous RA from the embryo.
Cycloheximide treatments were performed at a concentration of 5 lg/mL at stage 14. Embryos were exposed to cycloheximide 15 min prior to treatment with RA. Embryos were only cultured for 90 min before being fixed for in situ hybridization because longer treatments with cycloheximide essentially blocked development.
Embryo explants
Embryo explants were performed at stage 13 in 1· Modified Barth's Saline (MBS) by first making an incision through the center of the neural plate into the archenteron. The resulting flaps of tissue were folded back and removed at the point at which the walls of the archenteron met the archenteron floor; effectively isolating tissue from the floor of the archenteron to the ventral pole of the embryo. Explants were then treated with 1 lM RA, 1 lM RAA or control DMSO for 90 min, and fixed in MEMPFA overnight at 4°C.
4.4.
In situ hybridization
Whole-mount in situ hybridizations were performed according to Harland (1991) with minor modifications (Collop et al., 2006) . In addition the following modifications were incorporated: embryos were blocked in Tris buffered saline, 20% heat treated sheep serum; and the Proteinase K, and RNase A steps were omitted. Antisense riboprobes for Hand1 (Sparrow et al., 1998) , Xsal-1 (Hollemann et al., 1996) , Xfd-13 (FoxF1) (Koster et al., 1999) , XNkx-2.5 (Tonissen et al., 1994) , and XhoxC-10 (Christen et al., 2003) were labeled with Digoxygenin-labeled UTP (Roche Diagnostics) following the protocol by Harland (1991) except that incorporation of P 32 labeled nucleotides was omitted, and the transcribed riboprobes were resuspended in RNA hybridization buffer directly without alkaline hydrolysis. BM Purple (Roche Diagnostics) was used as the alkaline phosphatase substrate and embryos were fixed for twenty minutes in MEMPFA before removing endogenous pigment in 1% hydrogen peroxide, 5% formamide, and 0.5% SSC for several hours after the colour reaction. Embryos were visualized on a Leica MZ12 dissecting microscope and images were captured using Northern Eclipse software (Empix Imaging; Mississauga, ON, Canada).
4.5.
Morphometric analysis
To quantify the area of Hand1 expression in explants, the area of staining was outlined using Northern Eclipse software (Empix Imaging; Mississauga, ON, Canada) which subsequently calculated total area. Total staining area was then compared between groups by virtue of a one way ANOVA with a Tukey's post hoc test. The confidence interval was set at 95% with n values of 10 for each group. The experiment was done in triplicate and each individual experiment reached significance.
Length of the LPM expression domains at stage 36 were measured on Northern Eclipse software (Empix Imaging; Mississauga, ON, Canada). The expression domains were measured as the distance from the front of the cement gland to the posterior edge of the staining domain (we have denoted this distance x), divided by the distance from the front of the cement gland to the point at which the posterior edge of the body axis met the somites (denoted z; fraction x/z). The exception was the HoxC-10 domain which was instead measured as a fraction of the length from the most anterior point of the expression domain to the point at which the body wall met the somites (distance denoted y) divided by z (fraction y/ z). These values were then compared by a one way ANOVA with a confidence interval of 95% with a Tukey's post hoc test. A minimum n value of 8 was used for each treatment. The experiment was done in triplicate with each experiment reaching significance.
